Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

AMSBIO Introduce Herpes Virus Entry Mediator Product Range

publication date: Dec 15, 2017
 | 
author/source: AMSBIO

herpes Virus

AMSBIO has introduced a new range of Herpes Virus Entry Mediator (HVEM) products for use in immuno-oncology research. 

These new products will be of great interest to researchers studying TNFR family members such as CD137 (4-1BB), GITR, OX40, CD27, and other co-stimulatory proteins involved in B and T cell development, immune activation, and antitumor immune responses.

The AMSBIO range includes a suite of HVEM products including an HVEM/LIGHT cellular assay, recombinant LIGHT, BTLA, and HVEM proteins, HVEM and LIGHT expressing cell lines, as well as a BTLA:HVEM [Biotinylated] Inhibitor Screening Assay Kit to study these pathways.

HVEM, also known as CD270 or TNFSFR14 (Tumor Necrosis Factor Receptor Superfamily Member 14), is a cell surface receptor expressed on many immune cells, including T cells. HVEM plays a key role in herpes simplex virus infection. The interaction between HVEM and the viral protein Glycoprotein D (gD) is one of the first steps of herpes simplex virus (HSV) entry into the cell. Recently HVEM has also become an important immuno-oncology target after researchers discovered that HVEM is involved in the induction of apoptosis of tumor cells.

When HVEM interacts with a protein known as LIGHT (TNFSF14, CD258), it creates a co-stimulatory signal that activates lymphoid cells and amplifies the immune response. This means HVEM/LIGHT binding combines immune system amplification with a pro-apoptotic effect, providing a double punch against cancer, and therefore making it a particularly promising target for cancer drug discovery.

HVEM also can bind to a protein called BTLA (CD272, IgSF), which negatively regulates T-cell immune responses. Thus, HVEM can act as a molecular switch, either activating or inhibiting the immune response, depending which ligand it binds.


more about AMSBIO


more news from AMSBIO


 


If you have not logged into the website then please enter your details below.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events